Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Results of the consensus workshop for the relative importance of the evaluation criteria and their weight in the final score for each option. *The initially determined weights were refined after the case study experience by reducing the weight of the price criterion. ** Health economic or health outcomes data

From: Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait

Criterion Measures Ranking Initial Weights* Final Weights*
Savings versus originator Quantitative Primary 42.5% 35.0%
Equivalence with the reference product Qualitative 1 14.3% 16.2%
Stability and drug formulation Qualitative 2 11.9% 13.5%
Quality assurance Qualitative 3 9.9% 11.2%
Reliability of drug supply Qualitative 4 7.8% 8.8%
Macroeconomic benefit Qualitative 5 4.9% 5.5%
Real world outcomes** Qualitative 6 3.7% 4.2%
Pharmacovigilance Qualitative 7 2.9% 3.3%
Added value service related to product Qualitative 8 2.1% 2.3%